Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics
|
|
- Candace Reed
- 6 years ago
- Views:
Transcription
1 Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital
2 Objectives 1. Discuss the epidemiology of chemotherapyinduced cardiotoxicity (focus on changes in left ventricular function) in the context of the some specific agents. 2. Discuss the current approach to treatment of established cardiomyopathy from chemotherapeutic agents in the treatment.
3 Role of the Clinical Cardiologist Interaction of the oncologist with: General Cardiologist Often first line Heart Failure Specialist Severe LV Dysfunction Echocardiographer Questions related to reports or imaging quality/interpretation
4 Chemotherapy and cardiotoxicity Roles of the Cardiologist Clinical assessment Identifying risk factors Symptomatic Asymptomatic Can my patient get chemotherapy? Organizing Follow-up Medical therapy Echocardiography 2D 3D MUGA DEFINING CARDIOTOXICITY
5 Chemotherapy and cardiotoxicity: Anthracyclines Trastuzumab Kinase Inhibitors The Agents Others Other chemotherapeutic agents Radiation
6 Cumulative probability of developing doxorubicin-induced congestive heart failure (CHF) plotted against total cumulative dose of doxorubicin in all patients receiving the drug (3941 patients; 88 cases of congestive heart failure). Anthracyclines Shan K et al. Ann Intern Med 1996;125:47-58
7 Anthracyclines Oxidative stress with myocardial fibrosis and necrosis Possible direct toxic effect on local adrenergic neurotransmission that impacts myocardial contraction Apoptosis and dysregulation of calcium homeostasis in sarcoplasmic reticulum
8 Epidemiology AC Toxicity Anthracyclines Some studies suggest 60% 2-year mortality (older data, less SOC therapy) Over 50% of all patients exposed show some cardiac dysfunction up to 20 years later and 5% will have overt HF symptoms Acute, early and late toxicity Dose dependent
9 Epidemiology AC Toxicity Smith et al BMC Cancer AC Increases risk of cardiotoxicity by 5.43 fold Increases risk of sub-clinical cardiotoxicity by 6.25 fold Any cardiotoxicity is increased by 2.27 fold Risk of cardiac death increases by 4.94 fold Higher risk with bolus compared to infusions Lower risk with epirubicin and liposomal doxorubicin and with cardioprotective agents (dexrazoxane)
10 AC Toxicity
11 Trastuzumab HER2-receptor blockade HER2 Receptors are there for embryonic cardiac development Protection against cardiotoxins HER2 levels elevated in HF and LV Dysfunction (inverse correlation) Knockout Mice with no gene show signs of Dilated CMP and susceptibility to anthracycline induced cardiotoxicity
12 Trastuzumab (Herceptin) First signs were in Slamon et al. NEJM 2001 Phase III, 469 patients AC+ HER (also a group with paclitaxel) vs. AC alone in metastatic breast cancer 28% symptomatic/asymptomatic cardiotoxicity in patients receiving herceptin vs. 8% who did not. Among the patients with toxicity, most with NYHA III-IV were in the AC group with herceptin After CREC formed (Cardiac Review and Evaluation Committee) examined reviewed Range of 3-7% using single agent rx Incidence of severe HF and cardiac death ranges from 0.6% to 4%
13 Trastuzumab (Herceptin)
14 Kinase Inhibitors
15 Kinase Inhibitors Nat Rev Drug Disc 2011
16 Kinase Inhibitors Unintended inhibition of specific kinases Kinases in the cardiomyocyte that are essential for cell survival In study of GI stromal tumors, 18% of patients getting Sutent had CHF or > 15 point decline in EF (Chu et al. Lancet 2007) One other safety study of Tykerb (lapatinib) suggesting cardiotoxicity
17 Kinase Inhibitors No good predictors, to date Ongoing studies Human studies focus on imaging and biomarkers Animal studies focus on models of cardiotoxicity, as in zebra fish and rodent models to better understand CV development There are also potential CV benefits of these meds: Pulmonary HTN Autoimmune diabetes Restenosis post PCI Post MI remodeling Genetic forms of HCM
18 Therapies in Chemotherapy Associated Cardiotoxicity Defining cardiotoxicity remains a challenge Who do you treat? What therapy do you use? What is end point for therapy? Can you ever stop therapy?
19 Therapies in Chemotherapy Associated Cardiotoxicity Cardinale et al. Circ Treatment with ACEi based on troponin I elevation after HDC Started 1 month after last cycle HDC for 1 year Normal EF at baseline Primary Endpoint : Drop of > 10 units, less than 50%
20 Therapies in Chemotherapy Associated Cardiotoxicity Nakamae et al. Cancer patients CHOP with or without 80 mg Valsartan
21
22 Therapies in Chemotherapy Associated Cardiotoxicity Kalay et al. JACC patients getting anthracycline (ANT) Coreg 12.5 mg po qd started before ANT and up to 6 months after End Point was LVEF
23 Therapies in Chemotherapy Associated Cardiotoxicity Acar et al. JACC patients undergoing ANT therapy 40 mg of atorvastatin vs. no statin (anti-oxidative, anti-inflammatory) 1 cycle per month End point was LVEF
24 From Bench to Bedside Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M Am J Cardiol 2011;107:
25 Univariate analysis of predictors of cardiotoxicity The change of LVEF at 3 months was not predictive of later cardiotoxicity The change in L-S, R-S and troponins at 3 months was predictive of later cardiotoxicity
26 Results By multiple regression analysis, (1) a longitudinal strain; and, (2) hs-tn-i were independent predictors of later cardiotoxicity Whereas patients with both findings have a 9-fold increase in the risk of CIC, The absence of either confers significant protection where only 3% develop CIC
27 Summary Established therapies and novel therapies Definition of cardiotoxicity Management aimed specifically at cardiotoxicity Imaging of patients with (potential) cardiotoxicity Predicting Cardiotoxicity
28 Future Directions Cardiology-Oncology Link Clinical Care Cardiology consultation when, where? Follow-up Cardio-Oncology Program initiative
Cardiotoxicity: The View of the Cardiologist
Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac
More informationCancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors
Cardiotoxicity of Cancer Therapies: Pathogenesis, Diagnosis, and Management Edward T.H. Yeh, M.D. Cancer survivors Now nearly 12 million cancer survivors in U.S. according to NCI 15% were diagnosed 2+
More informationChemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY
Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer
More informationCV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long
CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Albert
More informationCardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient
Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Vijay U. Rao, MD, PhD, FACC, FASE Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart
More informationGuideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines
Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines Jennifer Liu, MD FACC FASE Director of CV Laboratories Associate Professor of Clinical Medicine Memorial Sloan Kettering
More informationAdvanced Echocardiography in the Evaluation of Chemotherapy Patients
Advanced Echocardiography in the Evaluation of Chemotherapy Patients Juan Carlos Plana, MD, FACC, FASE Co-Director, Cardio-Oncology Center Section of Cardiovascular Imaging Department of Cardiovascular
More informationCardio-oncology: Basics and Knowing When You Need an Echo
Cardio-oncology: Basics and Knowing When You Need an Echo Vera H. Rigolin, MD, FASE, FACC, FAHA Professor of Medicine Northwestern University Feinberg School of Medicine Medical Director, Echocardiography
More informationBuilding a Cardio-Oncology Program
Building a Cardio-Oncology Program Marielle Scherrer-Crosbie, MD, PhD Professor of Medicine Director of Echocardiography University of Pennsylvania Philadelphia, PA Co-Director, Cardio-Oncology Program
More informationCan point of care cardiac biomarker testing guide cardiac safety during oncology trials?
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University
More informationCardioOncology: The Promise and Pitfalls of Personalized Medicine
CardioOncology: The Promise and Pitfalls of Personalized Medicine Vijay U. Rao, MD, PhD, FACC, FASE, FHFSA Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart
More informationIan Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta
Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta Peer Reviewed Funding: CIHR, ACF, AI-HS Industry: Servier Canada Inc, RocheCanada Inc. What is your approach
More informationAnthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients
Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Scottish Cancer Trials Breast Group Meeting Thursday 2 nd February 2017 Dr Peter Henriksen Edinburgh Heart Centre
More informationCardio-oncology: Applying new echo technology to guide therapy
Cardio-oncology: Applying new echo technology to guide therapy Dinesh Thavendiranathan MD, SM, FRCPC, FASE Director, Ted Rogers Program in Cardiotoxicity Prevention Assistant Professor of Medicine Division
More informationPotpourri: Cardio-Oncology Cases
Potpourri: Cardio-Oncology Cases Judy Hung, MD Massachusetts General Hospital Harvard Medical School No disclosures; Thank Michael Picard and Tomas Neilan for cases 59 year old woman (sister diagnosed
More information03/14/2019. Scope of the Problem. Objectives
Cardiac Consideration During and After Breast Cancer Treatment Indu G. Poornima M.D Division of Cardiology Scope of the Problem 1 in 8 women will develop breast cancer 3.3 million women are survivors CVD
More informationHow to Evaluate the Heart of Elderly Patients
How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer
More informationCardiotoxicity Effects of Chemotherapeutic Drugs
Cardiotoxicity Effects of Chemotherapeutic Drugs Allan L Klein M.D. Director, Center of Pericardial Diseases Professor of Medicine Heart and Vascular Institute Cleveland Clinic President, ASE * No conflicts
More informationManaging LV Impairment with Cancer Therapies
British Society for Heart Failure Revalidation & Training Day London, March 2017 Managing LV Impairment with Cancer Therapies Zaheer Yousef BSc MBBS MD FESC FRCP Heart Muscle Diseases & Heart Function
More informationMultiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity
Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Cory V. Noel, M.D. Medical Director of CMR Pediatric Cardiology Outline What is meant by the term cardiotoxicity? Scope of
More informationVasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities )
Management of Cardiotoxicity due to Systemic Cancer Therapy Left Ventricular Dysfunction Type 1 cardiac dysfunction Type 2 cardiac dysfunction Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension
More informationCured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart
Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart Suma H. Konety, MD, MS Associate Professor, Cardiovascular Division University of Minnesota What is Cardio-Oncology?
More informationNew Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care
New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care Sandra M Swain, MD, FACP, FASCO Professor of Medicine Associate Dean for Research Development Georgetown
More informationCardio-Oncology at MHI. Kasia Hryniewicz, M.D.
Minneapolis Heart Institute at Abbott Northwestern Hospital Cardio-Oncology at MHI Cardiovascular Nursing Conference Kasia Hryniewicz, M.D. October 7 th, 2015 No disclosure 1 Why cardio-oncology? Background
More informationCardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer
Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Dr. Chris Fryer, Pediatric Oncologist, BC Children s Hospital Dr. Sean Virani, Founding Director, UBC Cardiovascular Oncology
More informationBreast Cancer and the Heart
Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications
More informationDisclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016
Disclosures Bayer Pharmaceuticals: clinical trial investigator KellyAnn Light-McGroary, MD, FACC Clinical Assistant Professor Cardiomyopathy Treatment Program University of Iowa Hospitals and Clinics Chief
More informationCancer and the heart: New evidence and open issues
Cancer and the heart: New evidence and open issues Dimitrios Farmakis, MD, PhD, FESC Assist. Professor, European University Cyprus Cardio-Oncology Clinic, Heart Failure Unit, Attikon Hospital Cardiac Clinic
More informationPractice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy
Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
More informationCardiac Toxicities Associated with Cancer Treatment
Cardiac Toxicities Associated with Cancer Treatment Hot Topics in Oncology Care 2017 Silicon Valley Oncology Nursing Society Christine Miaskowski, RN, PhD, FAAN American Cancer Society Clinical Research
More information12/16/16. Cardio-oncology: A practical overview for the cardiologist. Disclosures. Learner Objectives. Case 1
Disclosures I have no relevant financial disclosures. Division of Cardiology Department of Medicine Rajni Rao, MD Associate Professor of Medicine Cardio-oncology: A practical overview for the cardiologist
More informationRoohi Ismail-Khan, MD, MS
Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018
More informationΜυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα
Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Estimated and projected cancer survivors in USA de Moor JS et al. Cancer Epidemiol Biomarkers Prev 2013 Causes of
More informationSurvivorship: Managing Cardiac Toxicities
Survivorship: Managing Cardiac Toxicities Anecita Fadol, PhD, RN, FNP-BC, FAANP The University of Texas MD Anderson Cancer Center Learning Objectives Identify the causes of cardiac toxicity in cancer survivors
More informationPrevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline J Clin Oncol. 2016 Dec 5:JCO2016705400. [Epub ahead of print] Objectives: Improve the quality
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationSummary of risk management plan for Trazimera (trastuzumab)
Summary of risk management plan for Trazimera (trastuzumab) Summary of risk management plan for PF-05280014 (trastuzumab) 1 This is a summary of the RMP for PF-05280014. The RMP details important risks
More informationCardio oncology Double Jeopardy
Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection
More informationCase Study in Cancer and Cardiotoxicity
Case Study in Cancer and Cardiotoxicity JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY SERVICES UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON,
More informationCardiovascular outcomes in survivors of childhood cancer
Cardiovascular outcomes in survivors of childhood cancer Paul Nathan MD, MSc Director, AfterCare Program Division of Haematology/Oncology The Hospital for Sick Children, Toronto Conflicts Nothing to declare
More informationΓυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI
Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI Οικογενειακό ιστορικό νεοπλασιών: αρνητικό Σύντομο ατομικό ιστορικό:
More informationRECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE
RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE SARO ARMENIAN, DO, MPH ASSOCIATE PROFESSOR, DEPARTMENTS OF PEDIATRICS AND POPULATION SCIENCES DIRECTOR,
More informationConflict of interest: none declared
The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracycline-mediated cardiotoxicity C. Mornoş, A. Ionac, D. Cozma, S. Pescariu,
More informationTrastuzumab (IV) Monotherapy - 7 days
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital
More informationSIOG APAC th to 13 th July
SIOG APAC 2014 12 th to 13 th July Breast Cancer in Older Adults Cardiac Toxicity in Breast Cancer Dr Vivianne Shih, Pharm.D., BCPS, BCOP Specialist Pharmacist (Oncology) 1 Learning Objectives At the end
More informationA Step Forward in Cancer Patient Care:
Hong Kong Pharmacy Conference 2018 A Step Forward in Cancer Patient Care: The Experience of Oncology Pharmacist-Managed Trastuzumab Clinic in Queen Mary Hospital Amy Yuen Clinical Pharmacist 24 Oct 2017.
More informationMatters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer
CARDIAC TOXICITY MEDICAL ONCOLOGY Matters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer K. Towns MD,* P.L. Bedard MD, and S. Verma MD MSEd ABSTRACT Breast cancer
More informationDoes understanding the biology of cardiac injury from cancer therapy lead to new cardiac therapy? Carrie Geisberg MD, MSCI Vanderbilt University
Does understanding the biology of cardiac injury from cancer therapy lead to new cardiac therapy? Carrie Geisberg MD, MSCI Vanderbilt University No financial disclosures Disclosures Funded by: VCTRS career
More informationCardiovascular Imaging Endpoints in Oncology Clinical Trials
Cardiovascular Imaging Endpoints in Oncology Clinical Trials Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Cardio-Oncology Center of Excellence Director, Penn Center
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast
More informationCARDIOTOXICITY IN ONCOLOGY PRACTICE
CARDIOTOXICITY IN ONCOLOGY PRACTICE Evandro de Azambuja, MD, PhD Jules Bordet Institute, Brussels, Belgium CARDIOTOXICITY: THE MAGNITUDE OF THE PROBLEM Advances in cancer treatments have improved patients
More informationThe Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018
The Road to Improve Cardiovascular Health after Cancer S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018 Objective What are the cardiac complications in cancer
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More informationUpdate in Cardio-Oncology
Update in Cardio-Oncology Dr. Alexander Lyon BHF Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British Cardio-Oncology Society
More informationRedefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs
Redefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs Ana Barac, MD, PhD, FACC Associate Professor of Medicine, Georgetown University MedStar Heart and Vascular
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationStrain and Strain Rate Imaging How, Why and When?
Strain and Strain Rate Imaging How, Why and When? João L. Cavalcante, MD Advanced Cardiac Imaging Fellow Cleveland Clinic Foundation Disclosures: No conflicts of interest Movement vs Deformation Movement
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2013 June; 16(2): 178-183 Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with
More informationClinical Perspective: How Are We Doing From a Clinician s Point of View
Clinical Perspective: How Are We Doing From a Clinician s Point of View Steven E. Lipshultz, MD Department of Pediatrics University of Miami Miller School of Medicine Holtz Children s Hospital of the University
More informationDiastolic Heart Failure
Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationCardio-Oncology: Cardiac care specific to cancer patients and survivors. Learning Objectives
Cardio-Oncology: Cardiac care specific to cancer patients and survivors Lavanya Kondapalli MD, FACC Assistant Professor of Medicine, Division of Cardiology Director of Cardio-Oncology Learning Objectives
More informationExpert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx
Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx 5 th Annual Echo Florida, October 2016 Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine (Card/ Rad) University
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationWhen is strain assessment mandatory?
When is strain assessment mandatory? Geneviève Derumeaux University of Lyon France Presenter Disclosure Information Geneviève Derumeaux When is strain assessment mandatory? DISCLOSURE INFORMATION: None
More informationAnthracyclines in the elderly breast cancer patients
Anthracyclines in the elderly breast cancer patients Etienne GC Brain, MD PhD Medical Oncology Centre René Huguenin, Saint-Cloud & Group GERICO, FNCLCC, Paris Centre René Huguenin - Saint-Cloud Facts about
More informationCardiotoxicities of Cancer in Childhood Cancer Survivors
Cardiotoxicities of Cancer in Childhood Cancer Survivors Steven E. Lipshultz, MD Department of Pediatrics Wayne State University School of Medicine Children s Hospital of Michigan Detroit, MI, USA Stages
More informationExpert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx. No Real or Potential Conflict of Interests for this Talk CTRCD
Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine University of Kentucky / Gill Heart & Vascular Institute
More informationΦαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας. Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.
Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.Γεννηματάς Clinical Trials on Fibrinolysis N = 61.41 AMI pts, ( GUSTO I, GUSTOIIb,
More information4/5/2017. Chemotherapy Related Cardiac Dysfunction & How a Cardiology Oncology Clinic Can Help! Cancer. Cancer Treatment Patient.
hemotherapy Related ys & How a ardiology ncology linic an Help! April 22, 2017 Maria Anwar, BScharm, AR maria.anwar@ahs.ca Key Learning bjectives To provide a brief background about cardio oncology To
More informationCARDIAC ISSUES IN CANCER SURVIVORS Jean-Bernard Durand, M.D.
CARDIAC ISSUES IN CANCER SURVIVORS Jean-Bernard Durand, M.D. Hello, my name is John-Bernard Durand. I m an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center, and I ve been
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationLate Effects of Treatment on the Heart. Jennifer H. Jordan, PhD, MS William O. Ntim, MD, FACC, FACP
Late Effects of Treatment on the Heart Jennifer H. Jordan, PhD, MS William O. Ntim, MD, FACC, FACP Panel Speakers Jennifer H. Jordan, PhD, MS Assistant Professor, Cardiovascular Medicine Comprehensive
More informationThe breast cancer patient in the cardioncology unit
Review Article The breast cancer patient in the cardioncology unit Daniela Cardinale, Vincenzo Caruso, Carlo M. Cipolla Cardioncology Unit, Cardiology Division, IEO, European Istitute of Oncology, IRCCS,
More informationRADIATION HEART DISEASE: MANAGEMENT STRATEGIES
RADIATION HEART DISEASE: MANAGEMENT STRATEGIES AMMAR CHAUDHARY MBChB, ABIM, FRCPC ASSOCIATE CONSULTANT CARDIOLOGIST KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER - JEDDAH Scope of the Problem ~ 50
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:
More informationΟ ογκολογικός ασθενής και η καρδιά του
Ο ογκολογικός ασθενής και η καρδιά του Δημήτρης Φαρμάκης Αν. Καθηγητής, Πανεπιστήμιο Κύπρου Καρδιακή Ανεπάρκεια & Καρδιο-Ογκολογία, ΠΓΝ «Αττικόν» Disclosures Consultation fees, speaker honoraria or travel
More informationCardio-Oncology Toxicities and Management
Cardio-Oncology Toxicities and Management Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies April 21, 2017 Michel G. Khouri, MD Assistant Professor of Medicine Division
More informationClick to edit Master title style
Click to edit Master title style Cardio-Oncology: A Historical Perspective Past, Present and Future Susan Dent, MD, FRCPC Medical Oncologist, Duke Cancer Institute Professor of Medicine Associate Director,
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationImportance of CRT team for optimization of the results: a European point of view
Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare
More informationSusan P. D Anna MSN, APRN BC February 14, 2019
Is there Equal Opportunity in Heart Failure?? Susan P. D Anna MSN, APRN BC February 14, 2019 Disclosures: I have no financial disclosures. I am not an expert on this topic, but see a lot of women with
More informationThe Heart of the Matter: Issues in Cardio-Oncology Research
The Heart of the Matter: Issues in Cardio-Oncology Research Edith Pituskin RN MN Nurse Practitioner, Radiation Oncology, Cross Cancer Institute PhD (c), Faculty of Rehabilitation Medicine, University of
More informationRestrictive Cardiomyopathy
ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationCardio-Oncology: Past Present and Future
Cardio-Oncology: Past Present and Future Lakkana Suwannoi PharmD BCPS BCOP Division of Clinical Pharmacy Faculty of Pharmacy Mahidol University Bangkok THAILAND Outline I. Cardiovascular disease & cancer
More information1/27/2018 THE WAY FORWARD: AN EMERGING FIELD OF CARDIO-ONCOLOGY LEARNING OBJECTIVES. Cardiology and Oncology. Why to Discuss Together..
LEARNING OBJECTIVES THE WAY FORWARD: AN EMERGING FIELD OF CARDIO-ONCOLOGY MARIANNA KRIVE, DO ADVOCATE HEART INSTITUTE AMG-PARKSIDE CARDIOLOGY 1.Explain the foundation and the medical need for cardio-oncology
More informationVECTORS OF CONTRACTION
1/3/216 Strain, Strain Rate, and Torsion: Myocardial Mechanics Simplified and Applied VECTORS OF CONTRACTION John Gorcsan, MD University of Pittsburgh, Pittsburgh, PA Shortening Thickening Twisting No
More informationHeart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes
Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes DAVID S. H. BELL CHAIRMAN BELL, DSH. DIABETES CARE(2003)26:2433-41. Speaker s Bureau: AstraZeneca Novo Nordisk Janssen
More informationCARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY. Florian SCOTTE, MDPhD Suresnes, France
CARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY Florian SCOTTE, MDPhD Suresnes, France DISCLOSURES Consultant / Advisory Boards / Speaker: Tesaro, Sanofi, Roche, MSD, TEVA, Norgine, Prostrakan, Leo
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationHeart Failure. GP Update Refresher 18 th January 2018
GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British
More informationASNC INFORMATION STATEMENT
ASNC INFORMATION STATEMENT The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy Raymond R. Russell, MD, PhD, FASNC, a Jonathan
More information